Physician profile
James E Poist
NPI 1093701955
$2,660.82
in general payments reported to CMS, 2019-2025
37 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $167 · 2022: $751 · 2023: $496 · 2024: $235 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $402.42 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $378.11 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $201.08 | 2023-2024 | Myfembree, Gemtesa |
| Amgen INC. | $193.00 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $182.69 | 2019-2025 | |
| Hologic Sales and Service, LLC | $103.16 | 2019-2023 | Novasure, Aptima |
| Myovant Sciences INC. | $97.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.49 | 2019-2025 | |
| Roche Diagnostics Corporation | $87.21 | 2019 | |
| Organon LLC | $66.97 | 2023-2025 | Nexplanon |
| Becton, Dickinson and Company | $64.03 | 2022-2025 | Hemosphere |
| Shield Therapeutics INC | $63.87 | 2023-2025 | Accrufer |
| Mayne Pharma Commercial LLC | $54.82 | 2022-2024 | |
| Coopersurgical, INC. | $46.17 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $40.99 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $40.83 | 2020-2022 | |
| Exeltis, USA INC. | $38.39 | 2022-2023 | Slynd |
| Allergan, INC. | $37.16 | 2019-2020 | |
| Sage Therapeutics, LLC | $37.13 | 2019-2025 | Zurzuvae |
| Conmed Corporation | $36.19 | 2025 | Airseal, Vcare, Visiclear |
| Minerva Surgical, INC | $32.53 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2022 | |
| Millicent US INC | $31.65 | 2023 | Intrarosa |
| Merck Sharp & Dohme LLC | $29.17 | 2019-2024 | Gardasil 9, Gardasil |
| Amag Pharmaceuticals, INC. | $28.81 | 2019-2020 | |
| Duchesnay USA Incorporated | $28.41 | 2019 | |
| Therapeuticsmd, INC. | $27.01 | 2019-2022 | |
| Kci USA, INC. | $24.20 | 2019 | |
| Daiichi Sankyo INC. | $23.83 | 2019 | |
| Axonics, INC. | $20.86 | 2023 | Axonics |
| Mylan Pharmaceuticals INC. | $19.22 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.99 | 2025 | Qelbree |
| Urovant Sciences INC | $17.20 | 2022 | |
| Meditrina | $17.14 | 2025 | |
| Intuitive Surgical, INC. | $17.11 | 2019 | |
| Evofem Biosciences, INC. | $16.73 | 2022 | |
| Scynexis, INC. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Poist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.